DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)

Drugs

Volumn 63, Issue 7, 2003, Pages 673-682

  Curran, Monique P ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA TETANUS ACELLULAR PERTUSSIS HEPATITIS B RECOMBINANT INACTIVATED POLIOMYELITIS ADSORBED CONJUGATED HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA TOXOID; PNEUMOCOCCUS VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE ANTIBODY; POLYRIBOSYLRIBITOL PHOSPHATE ANTIGEN; RECOMBINANT VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; CLINICAL TRIAL; DIPHTHERIA; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEVER; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFECTION; INFECTION PREVENTION; INFLUENZA; INJECTION PAIN; IRRITABILITY; PERTUSSIS; POLIOMYELITIS; RESTLESSNESS; REVIEW; SIDE EFFECT; SOMNOLENCE; STREPTOCOCCUS INFECTION; TETANUS; VACCINATION;

ANTIBODY FORMATION; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT;

HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE SEROTYPE B; HEPATITIS B VIRUS; POLIOVIRUS; STREPTOCOCCUS;

EID: 0037247822     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363070-00004     Document Type: Review

References (42)

1. Meyerhoff AS, Weniger BG, Jacobs RJ, Economic value to parents of reducing the pain and emotional distress of childhood vaccine injections. Pediatr Infect Dis J 2001 Nov; 20 (11 Suppl.): S57-62
2. Rappuoli R, Locht C, Poolman J, et al. European Commission COST/STD Initiative. Report of the expert panel VIII. New vaccines, especially new combined vaccines. Vaccine 1996 May; 14 (7): 691-700
3. Hadler SC. Cost benefit of combining antigens. Biologicals 1994 Dec; 22 (4): 415-8
4. Halperin SA. Developing better paediatric vaccines: the case of pertussis vaccine. Biodrugs 1999; 12 (3): 175-91
5. Barkin RM, Pichichero ME. Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products. Pediatrics 1979 Feb; 63 (2): 256-60
6. Baraff LJ, Cody CL, Cherry JD. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 1984 Jan; 73 (1): 31-6
7. Long SS, Deforest A, Smith DG, et al. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990 Mar; 85 (3): 294-302
8. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997 Apr; 16 (4): S90-6
9. Patel SS, Wagstaff AJ. A cellular pertussis vaccine (Infanrix™-DTPa; SB-3): a review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection. Drugs 1996 Aug; 52 (2): 254-75
10. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000 Apr; 13 (2): 302-17
11. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol 2002 Jul; 67 (3): 433-9
12. Committee on Infectious Diseases. Recommended childhood immunization schedule-United States, 2002. Pediatrics 2002 Jan; 109: 162
13. Recommended childhood immunization schedule - United States, 2001. MMWR Morb Mortal Wkly Rep 2001 Jan 12; 50: 7-10 & 19
14. Sutter RW, Prevots DR, Cochi SL. Poliovirus vaccines: progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States. Pediatr Clin North Am 2000 Apr; 47 (2): 287-308
15. Andre FE. Development and clinical application of new polyvalent combined paediatric vaccines. Vaccine 1999 Mar 26; 17 (13-14): 1620-7
16. Decker MD, Edwards KM Combination vaccines: problems and promise. J Pediatr 2000 Sep; 137 (3): 291-5
17. Edwards KM, Decker MD. Combination vaccines. Infect Dis Clin North Am 2001 Mar; 15 (1): 209-30
18. Halperin SA, King J, Law B, et al. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three- component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis 1999 May; 28 (5): 995-1001
19. Eskola J, Olander RM, Hovi T, et al. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996; 348 (9043): 1688-92
20. Greenberg DP, Wong VK, Partridge S, et al. Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr Infect Dis J 2000 Dec; 19 (12): 1135-40
21. Pichichero ME, Latiolais T, Bernstein DI, et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants. Pediatr Infect Dis J 1997 Sep; 16 (9): 863-70
22. Eskola J, Ward J, Dagan R, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999 Dec 11; 354 (9195): 2063-8
23. Zepp F, Schmitt HJ, Kaufhold A, et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr 1997 Jan; 156 (1): 18-24
24. Schmitt HJ, von Kries R, Hassenpflug B. et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated polio virus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001 Aug; 20 (8): 767-74
25. GlaxoSmithKline. Summary of product characteristics (Infanrix hexa™). Rixensart: GlaxoSmithKline, 2002
26. Avdicová M, Prikazský, VV, Hudecková H, et al. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV- IPV/Hib vaccine compared to separate concomitant injections of DTPa- IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002 Nov; 161 (11): 581-7
27. Schmitt HJ, Knuf M, Ortiz E, et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000 Sep; 137 (3): 304-12
28. Blatter MM, Reisinger KS, Terwelp DR, et al. Immunogenicity of a combined diptheria-tetanus-acellular pertussis (DT-tricomponent Pa)-Hepatitis B (HB)-inactivated poliovirus (IPV) admixed with Haemophilus influenzae type b (Hib) vaccine in infants. Pediatr Res 1998; 43: A141
29. Pichichero ME, Blatter MM, Reisinger KS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B- inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002 Sep; 21 (9): 854-9
30. Poolman J, Kaufhold A, De Grave D, et al. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 2001 Mar 21; 19 (17-19): 2280-5
31. Crovari P, Zepp F, Dentico P, et al. Immunogenicity and reactogenicity of combined DTPA-HBV-IPV/HIB vaccine compared to concomitant administered DTPA-HBV-IPV and HIB vaccines given at 3, 5, and 11 months of age. Proceedings of the 19th Annual Meeting of the European Society for Paediatric Infectious Diseases (EPSID); 2001 Mar 26-28; Istanbul
32. Omenaca F, Garcia-Siella J, Boceta R, et al. Immunogenicity of a combined DTPa-HBV-IPV +/Hib vaccine in pre-term infants (<37 weeks) as a primary vaccination course. Proceedings of the Third World Congress of Pediatric Infectious Diseases; 2002 Nov 19-23; Santiago
33. Schmitt HJ, Petersen G, Corsaro B, et al. Immunogenicity and safety of a 7-valent pneumococcal conjugate vaccine (Prevenar®) coadministered with a DTaP-IPV-HBV/Hib vaccine (Infanrix hexa®). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA), 242
34. Saenger R, Dobbelaere L, Schuerman L. Immunogenicity and safety of DTPa-HBV-IPV/HIB coadministered with 7-valent pneumococcal conjugate vaccine [abstract]. Proceedings of the 3rd World Congress of Pediatric Infectious Diseases; 2002 Nov 19-23; Santiago
35. GlaxoSmithKline. Infanrix hexa™ (product monograph). GlaxoSmithKline, 2001. (Data on file)
36. Guiso N, Begué P, Cohen R, et al. Comparison of pertussis antibody levels in children up to 5 years of age primed at 2, 3, and 4 months and boostered in the second year of life with either DTPa or DTPw based combination vaccines, in France [abstract no. 62]. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2000 Sep 17-20; Toronto
37. Meyer CU, Guiso N, Begue P, et al. Cell-mediated immunity in children 2.5 to 5 years of age 1-3 years after vaccination with either DTPa or DTPw based combination vaccines in France [abstract no. 63]. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2000 Sep 17-20; Toroto
38. Meyer CU, Schmidtke P, Schuind E, et al. Cell-mediated immune response to pertussis antigens after primary vaccination with DTPa-HBV-Hib combined with IPV [abstract no. G-32]. Proceedings of the 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 1998 Sep 24; Mainz
39. Zepp F, Meyer CU, Kowalzol F, et al. Evaluation of the immunological memory induced by primary vaccination with Haemophilus influenzae type b (Hib) tetanus conjugate vaccine co-administered with various DTPa-based vaccines [abstract no. 242]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA), 359
40. Cohen R, Schuerman L. Reactogenicity of a new DTPA-HBV-IPV (+ &/Hib) vaccines after primary and booster doses [abstract no. P-31]. Proceedings of the 18th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2000 May 3-5; Noordwijk
41. Aristegui J, Diez-Delgado J, Mares J, et al. Reactogenicity of a hexavalent DTPa-HBV-IPV/Hib vaccine given as primary vaccination [abstract no. 12-PT297]. Proceedings of the 23rd International Congress of Pediatrics and 2nd International Congress on Pediatric Nursing; 2001 Sep 9-14; Beijing
42. Saenger R, Maechler G, Schuerman. Safety of a booster dose of DTPa-HBV-IPV/Hib compared to concomitant administration of DTPa-IPV/Hib and HBV vaccines. Proceedings of the Third World Congress of Pediatric Infectious Diseases; 2002 Nov 19-23: Santiago, 46